Related Experiment Video
Updated: Oct 17, 2025
Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
Published on: June 2, 2022
Methylprednisolone in Pediatric Cardiac Surgery: Is There Enough Evidence?
Annewil van Saet1, Gerdien A Zeilmaker-Roest2,3, Robert J Stolker1
1Department of Anesthesiology, Erasmus Medical Center, Rotterdam, Netherlands.
Insights
Methylprednisolone (MP) reduces inflammation after pediatric cardiac surgery, but its pharmacokinetics and long-term effects remain unclear. More research is needed to balance benefits against risks in different patient groups.
Area of Science:
- Pediatric Cardiac Surgery
- Pharmacology
- Immunology
Background:
- Corticosteroids, specifically methylprednisolone (MP), are widely used to mitigate the inflammatory response in pediatric cardiac surgery.
- Information regarding the pharmacokinetics and pharmacodynamics of MP in this population is limited, with significant interindividual variability observed.
- Neonates exhibit a larger volume of distribution for MP compared to other pediatric age groups.
Purpose of the Study:
- To review the existing evidence on methylprednisolone use in pediatric cardiac surgery.
- To assess the impact of MP on inflammatory mediators and patient outcomes.
- To identify gaps in knowledge regarding MP's efficacy, safety, and long-term effects.
Main Methods:
- Review of existing literature on perioperative methylprednisolone use in pediatric cardiac surgery.
- Analysis of studies examining inflammatory mediators, pharmacokinetics, and clinical outcomes.
- Evaluation of evidence regarding different MP dosages and administration timings.
Main Results:
- Perioperative MP decreases pro-inflammatory mediators and increases anti-inflammatory mediators, irrespective of dose (2 vs. 30 mg/kg) or timing of administration.
- MP shows potential benefits in specific patient subgroups but carries associated side effects.
- Limited data exists on short- to medium-term outcomes, with underpowered studies.
- No information is available on long-term outcomes like neurodevelopmental effects.
Conclusions:
- Methylprednisolone may offer a modest benefit in pediatric cardiac surgery, but this can be diminished by patient-specific factors and surgical management.
- The current lack of robust evidence leads to significant variations in clinical practice.
- There is a critical need for well-powered randomized controlled trials to clarify the role and optimize the use of MP in this setting.
Abstract:
Corticosteroids have been used to decrease the inflammatory response to cardiac surgery and cardiopulmonary bypass in children for decades. Sparse information is present concerning the pharmacokinetics and pharmacodynamics of corticosteroids in the context of pediatric cardiac surgery. There is large interindividual variability in plasma concentrations, with indications for a larger volume of distribution in neonates compared to other age groups. There is ample evidence that perioperative use of MP leads to a decrease in pro-inflammatory mediators and an increase in anti-inflammatory mediators, with no difference in effect between doses of 2 and 30 mg/kg. No differences in inflammatory mediators have been shown between different times of administration relative to the start of surgery in various studies. MP has been shown to have a beneficial effect in certain subgroups of patients but is also associated with side effects. In lower risk categories, the balance between risk and benefit may be shifted toward risk. There is limited information on short- to medium-term outcome (mortality, low cardiac output syndrome, duration of mechanical ventilation, length of stay in the intensive care unit or the hospital), mostly from underpowered studies. No information on long-term outcome, such as neurodevelopmental outcome, is available. MP may provide a small benefit that is easily abolished by patient characteristics, surgical techniques, and perfusion management. The lack of evidence leads to large differences in practice between and within countries, and even within hospitals, so there is a need for adequately powered randomized studies.
Related Concept Videos
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:21Skeletal Muscle Relaxants: Adverse Effects
Unlike...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...